Regulation of lipid metabolism and gene expression by fenofibrate in hamsters

Biochimica et Biophysica Acta- Molecular and Cell Biology of Lipids

Volumn 1533, Issue 3, 2001, Pages 220-232

  Guo, Qiu ^a   Wang, Pei Ran ^a   Milot, Denise P ^a   Ippolito, Marc C ^a   Hernandez, Melba ^a   Burton, Charlotte A ^a   Wright, Samuel D ^a   Chao, Yu Sheng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fenofibrate; Gene regulation; Hypolipidemia; Hypolipidemic drug; Syrian hamster

Indexed keywords

ACETIC ACID; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A OXIDASE; APOLIPOPROTEIN C3; CHOLESTEROL; FATTY ACID SYNTHASE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; LIPOPROTEIN LIPASE; LIVER ENZYME; MESSENGER RNA; MEVALONIC ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; FATTY ACID SYNTHESIS; GENE EXPRESSION; HAMSTER; LIPID METABOLISM; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CELLS, CULTURED; CHOLESTEROL; COENZYME A LIGASES; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROXYMETHYLGLUTARYL-COA SYNTHASE; LIPID METABOLISM; LIPIDS; LIVER; MALE; MESOCRICETUS; MODELS, ANIMAL; PROCETOFEN; RNA, MESSENGER;

ANIMALIA; CRICETINAE; MESOCRICETUS AURATUS;

EID: 0035980764     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-1981(01)00156-1     Document Type: Article

References (77)

1. The low-density lipoprotein pathway and its relation to atherosclerosis
2. The association of serum lipids, lipoproteins and apolipoproteins with coronary artery disease assessed by coronary arteriography
3. Cholesterol and mortality, 30 years of follow-up from the Framingham study
4. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
5. Drug therapy and the prevention of atherosclerosis in humans
6. Fibric acid derivatives
7. Triglyceride-lowering agents: Fibrates and nicotinic acid
8. Combination drug therapy for dyslipidemia
9. Overview of fenofibrate
10. Review of European clinical experience with fenofibrate
11. Mechanism of action of fibrates on lipid and lipoprotein metabolism
12. Influence of procetofen on lipid metabolism in normocholesterolemic rats
13. Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPARα and PPARγ activators
14. Induction of the acyl-coenzyme A synthetase gene by fibrates ad fatty acids is mediated by a peroxisome proliferator response element in the C promoter
15. Perturbation of developmental gene expression in rat liver by fibric acid derivatives: Lipoprotein lipase and α-fetoprotein as models
16. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase
17. Effects of clofibrate, bezafibrate, fenofibrate, and probucol on plasma lipolytic enzyme in normolipidaemic subjects
18. The biochemical pharmacology of fenofibrate
19. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia
20. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation
21. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
22. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
23. Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat
24. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: A potential physiologic basis for their mode of action
25. Drugs affecting lipoprotein disposition in laboratory animals
26. Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat
27. Rates of receptor-dependent and-independent low density lipoprotein uptake in the hamster
28. Effect of cholesterol and bile acids on the regulation of cholesterol metabolism in hamster
29. Aspects of cholesterol metabolism in normal and hypercholesterolemic syrian hamsters. Influence of fenofibrate
30. Effects of dietary cholesterol and fasting on hamster plasma lipoprotein lipids
31. Why prefer the golden Syrian hamster (Mesocricetus auratus) to the Wistar rat in experimental studies on plasma lipoprotein metabolism?
32. Cholesterol lowering and bile acid excretion in the hamster with cholestyramine treatment
33. The hyperlipidemic hamster as a model of experimental atherosclerosis
34. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
35. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo
36. 3-Hydroxy-3-methylglutaryl coenzyme A reductase from rat liver
37. 3-Hydroxy-3-methylglutaryl-CoA synthase from chicken liver
38. Protein measurement with the Folin phenol reagent
39. Reciprocal effect of energy utilization on palmitate oxidation and esterification in hepatocytes of fed rats
40. Advances in quantitative PCR technology: 5′ Nuclease assays
41. Real time quantitative PCR
42. TaqMan cytokine gene expression plate I
43. Structure and biochemical effects of fenofibrate
44. Regulation of the mevalonate pathway
45. Diurnal variation of HMG CoA reductase activity in rat intestine
46. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
47. Fatty acids activate chimera of the clofibric acid-activated receptor and the glucocorticoid receptor
48. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids
49. Biochemical mechanisms of induction of hepatic peroxisome proliferation
50. Regulation of gene expression by fatty acids and fibric acid derivatives: An integrative role for peroxisome proliferator activated receptors
51. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
52. Peroxisome proliferator-activated receptors, orphans with ligands and functions
53. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice
54. PPARα and PPARγ activators direct a tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
55. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
56. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene
57. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells
58. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver
59. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2
60. The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates
61. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice
62. Effects of fibrates on serum lipids and atherosclerosis
63. Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects
64. Clinical results with gemfibrozil and background to the Helsinki Heart Study
65. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia
66. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition
67. Cloning of human acetyl-CoA carboxylase cDNA
68. Structure of the coding sequence and primary amino acid sequence of acetyl-coenzyme A carboxylase
69. Complete nucleotide sequence of cDNA and predicted amino acid sequence of rat acyl-CoA oxidase
70. Linkage, evolution, and expression of the rat apolipoprotein A-I, C-III, and A-IV genes
71. Characterization of the mouse apolipoprotein Apoa-1/Apoc-3 gene locus: Genomic, mRNA, and protein sequences with comparisons to other species
72. Structure of mouse fatty acid synthase mRNA. Identification of the two NADPH binding sites
73. Human fatty acid synthase: Properties and molecular cloning
74. Rat mammary gland fatty acid synthase: Localization of the constituent domains and two functional polyadenylation/termination signals in the cDNA
75. The structure of the mouse lipoprotein lipase gene: A B1 repetitive element is inserted into the 3′ untranslated region of the mRNA
76. Molecular cloning and functional expression of a cDNA for mouse squalene synthase